Revisiting the role of TEG-PM in stroke prevention by drug selection for mono-antiplatelet medication following dual-antiplatelet treatment
CONCLUSION: The TEG-PM could be a tangible preprocessing in drug selection for MAPT following DAPT in patients with minor strokes or TIAs, especially for those with non-stented ICASs.PMID:38295427 (Source: Neuroendocrinology Letters)
Source: Neuroendocrinology Letters - January 31, 2024 Category: Endocrinology Authors: Lei Yan Wenzhao Liang Bingyang Zhao Zhongyu Zhao Kai Zhang Lingling Wang Jing Mang Source Type: research
Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction
We present the case of a 93-year-old man who was admitted for the treatment of cerebrovascular events. The patient was initially prescribed dual antiplatelet therapy with aspirin and clopidogrel along with lansoprazole, Hange-koboku-toh, and elobixibat. On day 36 after admission, the patient was found to have developed agranulocytosis. To improve his cerebrovascular prognosis, we first discontinued medications other than the anticoagulant medicines and initiated filgrastim. We discontinued clopidogrel 9 days after the discontinuation of the other medicines considering his low white blood cell count. One day after the di...
Source: Clinical Case Reports - January 29, 2024 Category: General Medicine Authors: Yuuri Kurokawa,
Ayako Watanabe,
Yuka Kashiwabara,
Saori Fukuda,
Shohei Nomoto,
Ayako Kuriki,
Kenji Momo Tags: CASE REPORT Source Type: research
Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & amp; Tobago
ConclusionsA large proportion of Trinidadian patients with CVD who are prescribed or may be prescribed clopidogrel carry genetic variants associated with clopidogrel resistance. These results emphasize the clinical need for further investigation into whetherCYP2C19*2 genotype should guide clopidogrel use for the cardiovascular disease population in Trinidad& Tobago.A slide deck is available for this article. (Source: Cardiology and Therapy)
Source: Cardiology and Therapy - January 29, 2024 Category: Cardiology Source Type: research
Effects of antiplatelet therapy on menstrual blood loss in reproductive-aged women: a systematic review
CONCLUSION: There is lack of high-quality data on the effects of antiplatelet therapy on menstrual bleeding. Aspirin may increase menstrual blood loss, at least in a minority of women, whereas the effects of P2Y12 inhibitors are unknown.PMID:38268520 | PMC:PMC10805676 | DOI:10.1016/j.rpth.2023.102295 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - January 25, 2024 Category: Hematology Authors: Eva K Kempers Johanna A van der Zande Paula M Janssen J érôme M J Cornette Jolien W Roos-Hesselink Marieke J H A Kruip Source Type: research
Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 25, 2024 Category: Cardiology Source Type: research
Author ’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 25, 2024 Category: Cardiology Source Type: research
The FGG c.952G > A variant causes congenital dysfibrinogenemia characterized by recurrent cerebral infarction: a case report
ConclusionThis case report expands the clinical phenotype spectrum associated with FGG c.952G>A (rs267606810) and underscores the significance of considering CD as a potential etiology for unexplained ischemic stroke, particularly in patients with a family history of coagulation disorders. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - January 24, 2024 Category: Neurology Source Type: research
The Complement System and C4b-Binding Protein: A Focus on the Promise of C4BPα as a Biomarker to Predict Clopidogrel Resistance
AbstractThe complement system plays a dual role in the body, either as a first-line defense barrier when balanced between activation and inhibition or as a potential driver of complement-associated injury or diseases when unbalanced or over-activated. C4b-binding protein (C4BP) was the first circulating complement regulatory protein identified and it functions as an important complement inhibitor. C4BP can suppress the over-activation of complement components and prevent the complement system from attacking the host cells through the binding of complement cleavage products C4b and C3b, working in concert as a cofactor fo...
Source: Molecular Diagnosis and Therapy - January 23, 2024 Category: Molecular Biology Source Type: research
Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program
CONCLUSION: A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype-guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.PMID:38253063 | DOI:10.1093/ajhp/zxae008 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 22, 2024 Category: Drugs & Pharmacology Authors: Christina L Aquilante Katy E Trinkley Yee Ming Lee Kristy R Crooks Emily C Hearst Simeon M Heckman Kaitlyn W Hess Elizabeth L Kudron James L Martin Carolyn T Swartz David P Kao Source Type: research
Impact of Platelet Reactivity on One-year Clinical Outcomes after Endovascular Therapy for Femoropopliteal Lesions
Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1 month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions [1]. However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet reactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared to aspirin [2]. Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Takuya Tsujimura, Osamu Iida, Mitsuyoshi Takahara, Kazuki Tobita, Daizo Kawasaki, Masahiko Fujihara, Sinya Sasaki, Hiroyoshi Yokoi, Kenji Suzuki, Toshiaki Mano Tags: Brief report Source Type: research
Impact of Platelet Reactivity on 1-Year Clinical Outcomes After Endovascular Therapy for Femoropopliteal Lesions
Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1 month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions.1 However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet r eactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared with aspirin.2 Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were ...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Takuya Tsujimura, Osamu Iida, Mitsuyoshi Takahara, Kazuki Tobita, Daizo Kawasaki, Masahiko Fujihara, Sinya Sasaki, Hiroyoshi Yokoi, Kenji Suzuki, Toshiaki Mano Tags: Brief Report Source Type: research
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation
ConclusionLowering the maintenance dose of ticagrelor from 90 to 60 mg bid effectively reduces bleeding risk without increasing thrombotic infarction risk in elderly, small-weight Asian females. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - January 20, 2024 Category: Drugs & Pharmacology Source Type: research
